Imperial College London
Portrait Picture

Professor Maria Kyrgiou

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Chair in Gynaecologic Oncology
 
 
 
//

Contact

 

+44 (0)20 7594 2177m.kyrgiou Website

 
 
//

Location

 

Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Joura:2019:10.1016/j.ejca.2019.04.032,
author = {Joura, EA and Kyrgiou, M and Bosch, FX and Kesic, V and Niemenen, P and Redman, CWE and Gultekin, M},
doi = {10.1016/j.ejca.2019.04.032},
journal = {European Journal of Cancer Care},
pages = {21--26},
title = {Human papillomavirus vaccination: The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy},
url = {http://dx.doi.org/10.1016/j.ejca.2019.04.032},
volume = {116},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Vaccines against human papillomavirus (HPV) are available in Europe since 2006. They have been highly effective in preventing infection and disease caused by the vaccine types. Clinical efficacy data are available for cervical, vulvovaginal and anal precancer and invasive cervical cancer. Disease reduction is best with early vaccination and a coverage of more than 70%. Gender-neutral vaccination provides direct protection for all men and improves the coverage. A good coverage is followed by herd protection of the unvaccinated men and women. School-based programs appear to be most effective; under the age of 15 years, two doses with an interval of 6–12 months are sufficient. From the age of 15 years, the standard regimen with three doses is recommended. A broad catch-up program for young adult women and men improves the effectiveness. The vaccines are also effective in sexually active women and men with previous but cleared infections. Vaccination in addition to local treatment of HPV-related disease appears to reduce recurrent or subsequent HPV-related disease. Combination of HPV vaccination and screening with HPV testing is the most effective approach to prevention of cervical cancer. The screening intervals may increase in the vaccinated cohorts. The upper age limit for vaccination remains to be evaluated, is country specific and depends on cost-effectiveness. The European Society of Gynaecologic Oncology and the European Federation for Colposcopy strongly support gender-neutral vaccination programs for children and young adolescents, with a catch-up program for young adults.
AU  - Joura,EA
AU  - Kyrgiou,M
AU  - Bosch,FX
AU  - Kesic,V
AU  - Niemenen,P
AU  - Redman,CWE
AU  - Gultekin,M
DO  - 10.1016/j.ejca.2019.04.032
EP  - 26
PY  - 2019///
SN  - 0961-5423
SP  - 21
TI  - Human papillomavirus vaccination: The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy
T2  - European Journal of Cancer Care
UR  - http://dx.doi.org/10.1016/j.ejca.2019.04.032
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000473270800004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.sciencedirect.com/science/article/pii/S0959804919302886?via%3Dihub
UR  - http://hdl.handle.net/10044/1/76110
VL  - 116
ER  -
Download